Patent · US Active

Sphingosine kinase inhibitors

US7338961B2 · kind B2 · utility

18Cited by
8References
5Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJun 15, 2006
Grant dateMar 4, 2008
Priority date
Expiry dateJun 15, 2026

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07C2603/74
  • WIPO fieldOrganic fine chemistry
  • WIPO sectorChemistry

Abstract

The invention relates to substituted adamantane compounds, pharmaceutical compositions thereof, processes for their preparation, and methods for inhibiting sphingosine kinase and for treating or preventing hyperproliferative disease, inflammatory disease, or angiogenic disease.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.